Teleflex (NYSE:TFX) Releases Earnings Results, Beats Expectations By $0.73 EPS

08 Nov 2026, 01:12 by Michael Walen · The Markets Daily

Teleflex (NYSE:TFX – Get Free Report) issued its earnings results on Thursday. The medical technology company reported $2.63 EPS for the quarter, beating analysts’ consensus estimates of $1.90 by $0.73, FiscalAI reports. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The business had revenue of $567.80 million during the quarter, compared to analysts’ expectations of $565.52 million. During the same period in the prior year, the business earned $3.67 earnings per share. The company’s quarterly revenue was up .1% compared to the same quarter last year.

Here are the key takeaways from Teleflex’s conference call:

Teleflex reported 3.0% pro forma adjusted constant-currency revenue growth and adjusted EPS of $2.63, up 39.2% year over year. It raised 2026 adjusted EPS guidance to $7.50–$7.75 while maintaining revenue growth guidance of 3.5%–4.5%; the EPS outlook includes a $0.31 benefit from tariff refunds.
Vascular and Surgical delivered solid growth of 4.6% and 5.1%, respectively, while Interventional returned to slight growth at 0.2%. Interventional remains affected by integration disruptions, though management reported progress in customer conversions, distributor transitions, and filling sales vacancies and expects gradual improvement.
The Acute Care and Interventional Urology divestiture remains subject to an FTC review following a Second Request, and its closing could slip from the targeted year-end timing into 2027. Teleflex said it remains confident in completing the transaction but acknowledged that the timing is outside its control.
Management expects a stronger financial profile in 2027, including operating margins of approximately 23% in the first year after the divestiture closes and lower interest expense and share count from debt reduction and buybacks. These improvements depend in part on completing the transaction and executing cost-saving and stranded-cost mitigation plans.
Teleflex sees EZPLAZ as a long-term opportunity with a U.S. market potential of at least $200 million, but expects immaterial revenue in 2026 and a contribution in 2027 as it builds the market and scales production. The company also highlighted progress on its Freesolve scaffold trials and increased R&D investment, while noting that the product’s data readout is still expected in late 2027.

Teleflex Trading Down 0.8%

Shares of NYSE:TFX traded down $1.26 during midday trading on Friday, reaching $150.89. The company’s stock had a trading volume of 948,142 shares, compared to its average volume of 718,324. The firm has a market cap of $6.39 billion, a price-to-earnings ratio of 18.33, a price-to-earnings-growth ratio of 0.94 and a beta of 0.85. Teleflex has a 1 year low of $100.18 and a 1 year high of $156.67. The company has a quick ratio of 2.12, a current ratio of 2.60 and a debt-to-equity ratio of 0.94. The business has a 50 day moving average price of $132.15 and a 200 day moving average price of $126.09.

Teleflex Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Monday, November 16th will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Monday, November 16th. Teleflex’s payout ratio is currently -5.84%.

Teleflex News Summary

Here are the key news stories impacting Teleflex this week:

Positive Sentiment: Royal Bank of Canada raised its price target to $175 from $155 and maintained an “outperform” rating, implying about 16% upside from the cited share price. Royal Bank of Canada rating
Positive Sentiment: Wells Fargo increased its target to $167 from $138, while keeping an “equal weight” rating. Mizuho also raised its target, to $160. Wells Fargo rating Mizuho price target
Positive Sentiment: Adjusted third-quarter EPS of $2.63 topped analyst estimates of about $1.90. Revenue of $567.8 million also narrowly exceeded expectations. Third-quarter results and outlook
Neutral Sentiment: Teleflex declared a quarterly dividend of $0.34 per share, equivalent to $1.36 annually and a yield of about 0.9%. Dividend announcement
Negative Sentiment: Revenue grew only 0.2% year over year, and adjusted EPS fell from $3.67 a year earlier. The modest reported growth may limit enthusiasm despite the earnings beat. Third-quarter results and outlook

Analysts Set New Price Targets

Several research firms recently issued reports on TFX. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a research note on Monday, September 21st. UBS Group lifted their target price on Teleflex from $145.00 to $158.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. Mizuho set a $160.00 price target on shares of Teleflex in a research note on Friday. Truist Financial reduced their price target on shares of Teleflex from $150.00 to $142.00 and set a “hold” rating on the stock in a research report on Wednesday, October 14th. Finally, Wall Street Zen raised Teleflex from a “hold” rating to a “buy” rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $160.80.

Get Our Latest Stock Analysis on Teleflex

About Teleflex

(Get Free Report)

Teleflex Incorporated is a global medical technology company that develops, manufactures and markets specialty medical devices. Its products are designed to support healthcare professionals in critical care and procedural settings, including vascular access, interventional cardiology and radiology, anesthesia, respiratory care, emergency medicine, surgical applications and urology.